Differential binding of Shiga toxin 2 to human and murine neutrophils

References

1. Armstrong G. D., Mulvey G. L., Marcato P., Griener T. P., Kahan M. C., Tennent G. A., Sabin C. A., Chart H., Pepys M. B. 2006; Human serum amyloid P component protects against Escherichia coli O157 : H7 Shiga toxin 2 in vivo : therapeutic implications for hemolytic-uremic syndrome. J Infect Dis 193:1120–1124 [CrossRef]
   [Google Scholar]
2. Beutin L., Krause G., Zimmermann S., Kaulfuss S., Gleier K. 2004; Characterization of Shiga toxin-producing Escherichia coli strains isolated from human patients in Germany over a 3-year period. J Clin Microbiol 42:1099–1108 [CrossRef]
   [Google Scholar]
3. Bitzan M., Richardson S., Huang C., Boyd B., Petric M., Karmali M. A. 1994; Evidence that Verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro . Infect Immun 62:3337–3347
   [Google Scholar]
4. Brigotti M., Caprioli A., Tozzi A. E., Tazzari P. L., Ricci F., Conte R., Carnicelli D., Procaccino M. A., Minelli F. other authors 2006; Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol 44:313–317 [CrossRef]
   [Google Scholar]
5. Cherla R. P., Lee S. Y., Tesh V. L. 2003; Shiga toxins and apoptosis. FEMS Microbiol Lett 228:159–166 [CrossRef]
   [Google Scholar]
6. Downey G. P., Doherty D. E., Schwab B. III, Elson E. L., Henson P. M., Worthen G. S. 1990; Retention of leukocytes in capillaries: role of cell size and deformability. J Appl Physiol 69:1767–1778
   [Google Scholar]
7. Flagler M. J., Strasser J. E., Chalk C. L., Weiss A. A. 2007; Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect Immun 75:760–765 [CrossRef]
   [Google Scholar]
8. Fraser M. E., Fujinaga M., Cherney M. M., Melton-Celsa A. R., Twiddy E. M., O'Brien A. D., James M. N. 2004; Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157 : H7. J Biol Chem 279:27511–27517 [CrossRef]
   [Google Scholar]
9. Fukuda M. N., Dell A., Oates J. E., Wu P., Klock J. C., Fukuda M. 1985; Structures of glycosphingolipids isolated from human granulocytes. The presence of a series of linear poly- N -acetyllactosaminylceramide and its significance in glycolipids of whole blood cells. J Biol Chem 260:1067–1082
   [Google Scholar]
10. Geelen J. M., van der Velden T. J., Te Loo D. M., Boerman O. C., van den Heuvel L. P., Monnens L. A. 2007; Lack of specific binding of Shiga-like toxin (Verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrol Dial Transplant 22:749–755 [CrossRef]
    [Google Scholar]
11. Hawkins P. N., Tennent G. A., Woo P., Pepys M. B. 1991; Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 84:308–316
    [Google Scholar]
12. Head S. C., Karmali M. A., Lingwood C. A. 1991; Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 266:3617–3621
    [Google Scholar]
13. Kaplan B. S., Meyers K. E., Schulman S. L. 1998; The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9:1126–1133
    [Google Scholar]
14. Karmali M. A., Petric M., Lim C., Fleming P. C., Steele B. T. 1983; Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet 2:1299–1300
    [Google Scholar]
15. Kimura T., Tani S., Matsumoto Yi Y., Takeda T. 2001; Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J Biol Chem 276:41576–41579 [CrossRef]
    [Google Scholar]
16. Kitov P. I., Sadowska J. M., Mulvey G., Armstrong G. D., Ling H., Pannu N. S., Read R. J., Bundle D. R. 2000; Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403:669–672 [CrossRef]
    [Google Scholar]
17. Kuligowski M. P., Kitching A. R., Hickey M. J. 2006; Leukocyte recruitment to the inflamed glomerulus: a critical role for platelet-derived P-selectin in the absence of rolling. J Immunol 176:6991–6999 [CrossRef]
    [Google Scholar]
18. Liu J., Akahoshi T., Sasahana T., Kitasato H., Namai R., Sasaki T., Inoue M., Kondo H. 1999; Inhibition of neutrophil apoptosis by Verotoxin 2 derived from Escherichia coli O157 : H7. Infect Immun 67:6203–6205
    [Google Scholar]
19. Macher B. A., Klock J. C. 1980; Isolation and chemical characterization of neutral glycosphingolipids of human neutrophils. J Biol Chem 255:2092–2096
    [Google Scholar]
20. Marcato P., Vander Helm K., Mulvey G. L., Armstrong G. D. 2003; Serum amyloid P component binding to Shiga toxin 2 requires both A subunit and B pentamer. Infect Immun 71:6075–6078 [CrossRef]
    [Google Scholar]
21. Menge C., Eisenberg T., Stamm I., Baljer G. 2006; Comparison of binding and effects of Escherichia coli Shiga toxin 1 on bovine and ovine granulocytes. Vet Immunol Immunopathol 113:392–403 [CrossRef]
    [Google Scholar]
22. Mulvey G., Vanmaele R., Mrazek M., Cahill M., Armstrong G. 1998; Affinity purification of Shiga-like toxin I and Shiga-like toxin II. J Microbiol Methods 32:247–252 [CrossRef]
    [Google Scholar]
23. Mulvey G. L., Marcato P., Kitov P. I., Sadowska J., Bundle D. R., Armstrong G. D. 2003; Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 187:640–649 [CrossRef]
    [Google Scholar]
24. Nataro J. P., Kaper J. B. 1998; Diarrheagenic Escherichia coli . Clin Microbiol Rev 11:142–201
    [Google Scholar]
25. Taguchi T., Uchida H., Kiyokawa N., Mori T., Sato N., Horie H., Takeda T., Fujimoto J. 1998; Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int 53:1681–1688 [CrossRef]
    [Google Scholar]
26. Tazzari P. L., Ricci F., Carnicelli D., Caprioli A., Tozzi A. E., Rizzoni G., Conte R., Brigotti M. 2004; Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin Cytom 61:40–44
    [Google Scholar]
27. te Loo D. M., Monnens L. A., van Der Velden T. J., Vermeer M. A., Preyers F., Demacker P. N., van Den Heuvel L. P., van Hinsbergh V. W. 2000; Binding and transfer of Verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 95:3396–3402
    [Google Scholar]
28. te Loo D. M., Heuvelink A. E., de Boer E., Nauta J., van der Walle J., Schroder C., van Hinsbergh V. W., Chart H., van de Kar N. C., van den Heuvel L. P. 2001a; Vero cytotoxin binding to polymorphonuclear leukocytes among households with children with hemolytic uremic syndrome. J Infect Dis 184:446–450 [CrossRef]
    [Google Scholar]
29. te Loo D. M., van Hinsbergh V. W., van den Heuvel L. P., Monnens L. A. 2001b; Detection of Verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol 12:800–806
    [Google Scholar]
30. Winter K. R., Stoffregen W. C., Dean-Nystrom E. A. 2004; Shiga toxin binding to isolated porcine tissues and peripheral blood leukocytes. Infect Immun 72:6680–6684 [CrossRef]
    [Google Scholar]